Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.
McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH, Chan DW, Diaz J, Izbicka E, Kagan J, Malehorn DE, Malik G, Oelschlager D, Partin A, Randolph T, Rosenzweig N, Srivastava S, Srivastava S, Thompson IM, Thornquist M, Troyer D, Yasui Y, Zhang Z, Zhu L, Semmes OJ. McLerran D, et al. Among authors: izbicka e. Clin Chem. 2008 Jan;54(1):44-52. doi: 10.1373/clinchem.2007.091470. Epub 2007 Nov 2. Clin Chem. 2008. PMID: 17981926 Free PMC article.
Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility.
Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Srivastava S, Thompson I, Welsh MJ, White N, Winget M, Yasui Y, Zhang Z, Zhu L. Semmes OJ, et al. Among authors: izbicka e. Clin Chem. 2005 Jan;51(1):102-12. doi: 10.1373/clinchem.2004.038950. Clin Chem. 2005. PMID: 15613711
Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer.
Grizzle WE, Adam BL, Bigbee WL, Conrads TP, Carroll C, Feng Z, Izbicka E, Jendoubi M, Johnsey D, Kagan J, Leach RJ, McCarthy DB, Semmes OJ, Srivastava S, Srivastava S, Thompson IM, Thornquist MD, Verma M, Zhang Z, Zou Z. Grizzle WE, et al. Among authors: izbicka e. Dis Markers. 2003-2004;19(4-5):185-95. doi: 10.1155/2004/546293. Dis Markers. 2003. PMID: 15258333 Free PMC article.
The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology.
Grizzle WE, Semmes OJ, Basler J, Izbicka E, Feng Z, Kagan J, Adam BL, Troyer D, Srivastava S, Thornquist M, Zhang Z, Thompson IM. Grizzle WE, et al. Among authors: izbicka e. Urol Oncol. 2004 Jul-Aug;22(4):337-43. doi: 10.1016/j.urolonc.2004.04.008. Urol Oncol. 2004. PMID: 15283893 Review.
A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer.
Tolcher AW, Chi K, Kuhn J, Gleave M, Patnaik A, Takimoto C, Schwartz G, Thompson I, Berg K, D'Aloisio S, Murray N, Frankel SR, Izbicka E, Rowinsky E. Tolcher AW, et al. Among authors: izbicka e. Clin Cancer Res. 2005 May 15;11(10):3854-61. doi: 10.1158/1078-0432.CCR-04-2145. Clin Cancer Res. 2005. PMID: 15897586 Clinical Trial.
A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
Tolcher AW, Kuhn J, Schwartz G, Patnaik A, Hammond LA, Thompson I, Fingert H, Bushnell D, Malik S, Kreisberg J, Izbicka E, Smetzer L, Rowinsky EK. Tolcher AW, et al. Among authors: izbicka e. Clin Cancer Res. 2004 Aug 1;10(15):5048-57. doi: 10.1158/1078-0432.CCR-03-0701. Clin Cancer Res. 2004. PMID: 15297406 Clinical Trial.
92 results